Company news

Ensysce Biosciences, Inc. news in 2022

Ensysce Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

December 18, 2022

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

December 6, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

December 4, 2022

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

November 13, 2022

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

November 13, 2022

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

October 30, 2022

Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study

October 27, 2022

Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference

October 11, 2022

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

September 21, 2022

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

September 7, 2022

Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting

September 5, 2022

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

August 30, 2022

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

August 23, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 22, 2022

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

August 10, 2022

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

August 8, 2022

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 26, 2022

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

July 12, 2022

Ensysce Biosciences Secures $8 Million Convertible Note Financing

June 30, 2022

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

June 26, 2022

Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

June 20, 2022

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

May 22, 2022

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

May 11, 2022

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

May 4, 2022

Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

May 4, 2022

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

April 17, 2022

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 30, 2022

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

March 23, 2022

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

February 7, 2022

Ensysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting

January 18, 2022

Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid

January 9, 2022

Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference

January 4, 2022

Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614

January 3, 2022

Calls in 2022

Decks in 2022